IN8bio announced updated clinical data showing that their DeltEx DRI gamma-delta T cell therapy for newly diagnosed glioblastoma patients achieved a median progression-free survival of 13.0 months and a median overall survival exceeding 19.5 months, significantly better than the standard-of-care median overall survival of 13.2 months. The therapy was well tolerated with no serious side effects and demonstrated immune system improvements that may contribute to better outcomes. These promising results suggest DeltEx DRI could change the treatment landscape for glioblastoma, a cancer with little progress in survival rates over the past 20 years. Further studies will be important to confirm these findings and potentially bring a new treatment option to patients.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
